Skip to main content
Premium Trial:

Request an Annual Quote

Aventis and Graffinity Sign Drug Development Deal

NEW YORK, May 31 - Aventis Pharma and chemical microarray developer Graffinity Pharmaceutical Design have signed a collaboration to identify leads for Aventis' drug targets, the two companies said Thursday. 

Financial details were not disclosed.

Graffinity, based in Heidelberg, Germany, has developed small-molecule microarrays that identify which compounds bind favorably with a protein drug target. 

"Graffinity's technologies are aimed at the rapid and cost effective discovery of new chemical entities, a step beyond high throughput screening," Dirk Vetter, CEO of Graffinity, said in a statement. "We start with a target gene and move through protein expression, screening on chemical microarrays and our proprietary RAISE technology (Rapid Array Informed Structure Evolution) to explore unprecedented chemical space and create potentially high value lead compounds," he added.

The company currently has collaborations with American Diagnostica, in Greenwich, Conn., German pharmaceutical company BASF / Knoll, and M-phasys, a German biotechnology company. In April, Graffinity completed a 30.6 million euro ($25.9 million) private funding round.  
The Scan

Shape of Them All

According to BBC News, researchers have developed a protein structure database that includes much of the human proteome.

For Flu and More

The Wall Street Journal reports that several vaccine developers are working on mRNA-based vaccines for influenza.

To Boost Women

China's Ministry of Science and Technology aims to boost the number of female researchers through a new policy, reports the South China Morning Post.

Science Papers Describe Approach to Predict Chemotherapeutic Response, Role of Transcriptional Noise

In Science this week: neural network to predict chemotherapeutic response in cancer patients, and more.